While we speculate that the synergistic effects observed in vivo may, in part, be mediated by LCRF‐0006‐enhanced tumor delivery of bortezomib, previous studies have also demonstrated the ability of ADH‐1 to enhance tumor response to chemotherapeutic agents independently of increasing drug delivery to tumors.21 This evidence concerns the gene ADH1A and neoplasm.